Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
No fewer than four ADCs with this target start human testing.
On a cross-trial basis varegacestat beats Ogsiveo.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
